Stock OMGA OMEGA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Omega Therapeutics, Inc.

Equities

OMGA

US68217N1054

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-02 EDT 		5-day change 1st Jan Change
2.76 USD +11.29% Intraday chart for Omega Therapeutics, Inc. +17.45% -8.31%
04-16 Omega Therapeutics CFO Joshua Reed to Depart MT
04-16 Omega Therapeutics, Inc. Announces Executive Changes, Effective as of May 31, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Omega Therapeutics, Inc. Designates Barbara Chan as Principal Accounting Officer, Effective as of May 31, 2024
Omega Therapeutics, Inc. Presents New Preclinical Data At AACR 2024 Supporting the Potential of Precision Epigenomic Control
Omega Therapeutics Cuts Headcount by 35%, Narrows Q4 Loss
Omega Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Omega Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Omega Therapeutics Announces Research Collaboration with Novo Nordisk to Develop Novel Therapeutic for Obesity Management
Sector Update: Health Care Stocks Stronger Late Afternoon
Top Midday Gainers
Novo Nordisk Collaborates With Omega Therapeutics, Cellarity on Cardiometabolic Diseases Research
Top Premarket Gainers
Wegovy maker Novo Nordisk enters research tie-ups with US biotech firms
Novo Nordisk Signs Research Deals With Omega Therapeutics, Cellarity
Novo Nordisk : accords de recherche avec Omega et Cellarity
Novo Nordisk signe des partenariats de recherche avec des biotechs américaines
Omega Therapeutics, Inc. Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis
Omega Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Omega Therapeutics, Inc. Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC
Omega Therapeutics Study of OTX-2002 Shows High Engagement With Patients, Without Dose-Limiting Toxicities
Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO I Trial
Omega Therapeutics, Inc. Announces Board Changes
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OMGA Stock
  4. News Omega Therapeutics, Inc.
  5. Other languages